Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 18/20 | 0.73 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.73 |
| ▸ | PSMB9 | P28065 | 5/20 | 0.73 |
| ▸ | PSMB6 | P28072 | 5/20 | 0.73 |
| ▸ | PSMB10 | P40306 | 5/20 | 0.73 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.73 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.73 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.73 |
| ▸ | PSMA2 | P25787 | 4/20 | 0.73 |
| ▸ | PSMA3 | P25788 | 4/20 | 0.73 |
| ▸ | PSMA4 | P25789 | 4/20 | 0.73 |
| ▸ | PSMA5 | P28066 | 4/20 | 0.73 |
| ▸ | PSMB4 | P28070 | 4/20 | 0.73 |
| ▸ | PSMB3 | P49720 | 4/20 | 0.73 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.73 |
| ▸ | PSMA6 | P60900 | 4/20 | 0.73 |
| ▸ | PSMA8 | Q8TAA3 | 4/20 | 0.73 |
| ▸ | PSMB7 | Q99436 | 4/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ixazomib SCHEMBL29353014 | 0.85 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL3742758 | 0.85 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL18088836 | 0.85 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826826 | 0.83 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826825 | 0.83 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL29454797 | 0.82 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL12391076 | 0.79 | PSMB5 (0.84) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL23641263 | 0.78 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL3753435 | 0.77 | PSMB5 (0.85) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL24224218 | 0.77 | PSMB5 (0.67) | PSMB5PSMB8PSMB9PSMB6PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARM INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3052105-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | Millennium Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051067-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR LUPUS NEPHRITIS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250238-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | PSMB5 2121/4885PSMB8 2379/4885PSMB9 2129/4885 |
| US-20180099000-A1 | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis | SSB, ME1, SLC16A1 | PSMB5 1893/4885PSMB8 2293/4885PSMB9 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.